Drug Profile
Research programme: antidepressents - Kamat Pharmatech
Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Kamat Pharmatech
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Depressive disorders
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for clinical-Phase-Unknown development in Depressive disorders in USA (PO)
- 15 Nov 2016 Clinical trials in Depressive disorders in USA (PO)